Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This report presents the diagnostic value of brush cytology in gastric cancer. Gastric biopsies and brush cytology were performed in 155 patients with gastric cancer and 48 with benign gastric disease. The positive rate for biopsy and brush cytology in cancer patients (including 11 cases of early gastric cancer) was 74.2% and 76.8% respectively. The positive rate of biopsy with concomitant brush cytology was 87.7, which was superior to that of biopsy or brush cytology alone (p less than 0.01). In 29 cases of gastric cancer involving the cardiac region. 20 were biopsy positive (69%) and 22 were brush cytology positive (75.9%). Biopsy with brush cytology was positive in 27 cases (93.1%) and gave better results than biopsy alone (p less than 0.01). The positive rate of biopsy with concomitant brush cytology in Borrmann type I, II, and III lesions (89.7%) was significantly higher than in Borrmann type IV lesions (50%). In the 48 patients with benign gastric lesion, biopsy and brush cytology each provided two false positives. The study shows that the combination of biopsy and brush cytology increases diagnostic accuracy for gastric cancer.
 ...
PMID:Value of biopsy and brush cytology in the diagnosis of gastric cancer. Shanghai Gastrointestinal Endoscopy Cooperative Group, People's Republic of China. 710 23

A 71-year-old man with Borrmann type 3 gastric cancer with multiple liver metastases had been treated with 5'-DFUR 1400 mg/m2/day, p.o. day 1-day 4/2w and CDDP 80 mg/m2 i.v. day 5/4w, which was repeated for 4 cycles. After 2 cycle treatment, all metastatic lesions in the liver disappeared on the computed tomography scan, indicating a complete response. The primary gastric lesion was reduced, indicating a partial response. There was no significant side effect during the 4 cycles of this therapy. He is alive 6 months after the therapy with a partial response. This 5'-DFUR and CDDP combination therapy seemed to be effective for advanced gastric cancer.
 ...
PMID:[A successful 5'-DFUR and CDDP combination therapy for an advanced gastric cancer complicated with multiple liver metastases]. 766 74

Penetration of gastric cancer through the wall is important because the treatment modality and prognosis are accordingly different. A prospective study was performed to assess the value of transabdominal ultrasonography in the differentiation of early gastric cancer limited within the mucosa and submucosa from advanced cancer extending into the muscle layer. Fifteen patients with early gastric cancer and 29 patients with advanced gastric cancer were evaluated preoperatively and compared with histological findings. Patients were referred after endoscopy and sonologists were informed of the site of the gastric lesions. Patients ingested 600-800 ml of boiled water and transabdominal ultrasonography of the gastric lesion was accomplished using a commercially available ultrasound equipment with 5.0 and 3.5 MHz transducers. Using the intact middle hyperechoic layer on sonogram as the criterion for early cancer, 10 of 15 patients with early gastric cancer and 27 of 29 patients with advanced gastric cancer were correctly diagnosed (84%). Fourteen of 15 cases with early gastric cancer showed a thickness of the lesion below 1.0 cm, while seven of 29 cases with advanced cancer showed a thickness 1.0 cm or less. We believe that transabdominal sonography may be a valuable method in the differentiation between early and advanced gastric cancer.
 ...
PMID:Transabdominal US staging of gastric cancer. 782 26

An early phase II clinical study of RP56976 (docetaxel), a new semisynthetic agent, was conducted in patients with apparatus digestorius cancer. Two or more intravenous doses of 60 mg/m2 were administered with dose-free intervals of 3-4 weeks. Of the 44 patients enrolled, 32 patients (15 patients with gastric cancer, 16 patients with colon cancer, and 1 patient with pancreatic cancer) completed the scheduled course of treatment. For antitumor efficacy in the 15 patients with gastric cancer that completed the study, 3 showed a partial response (PR)(20.0%). Of the 16 patients with colon cancer that completed the study, 1 showed a partial response (PR)(6.3%). No efficacy was noted in the patient with pancreatic cancer. All three patients with gastric cancer showing a partial response (PR) to docetaxel had displayed no response to previous chemotherapy. Evaluation was made for the primary gastric lesion and metastatic lesions in cervical lymph nodes and liver. The most frequent adverse reactions included leukopenia (100%) and neutropenia (97.2%) and subjective/objective adverse reactions included alopecia (80.6%), anorexia (72.2%), fatigue (52.8%), fever (47.2%) nausea/vomiting (47.2%), and diarrhea (38.9%). Leukopenia was of Grade III or more in 75.0% of the patients and neutropenia was of Grade III or more in 91.7%. All other adverse reactions were acceptable. The results suggest that docetaxel is an effective anticancer agent for gastric cancer.
 ...
PMID:[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract]. 794 88

A 65-year-old man complaining of nausea and loss of appetite was diagnosed as having Borrmann type 3 gastric cancer with multiple liver metastasis. He was treated for 5 days with bolus injections of l-leucovorin (l-LV: 100 mg/m2/day) followed by 5-fluorouracil (5-FU; 370 mg/m2/day), and this was repeated every 4 weeks. The computed tomography scan after 3 cycles showed an approximately 70% decrease in the size of metastatic lesions, indicating a partial response. The primary gastric lesion also showed a partial response. There were modest but tolerable side effects such as diarrhea. After 3 cycles, the patient was discharged and was given oral 5-FU preparation. He died 9 months after initial chemotherapy with a response duration of 5 months. This l-LV and 5-FU combination therapy appears useful for advanced gastric cancer.
 ...
PMID:[A case of advanced gastric cancer complicated with multiple liver metastasis successfully treated with l-LV and 5-FU combination]. 818 47

In order to study the mechanism of cancer metastasis, AH100B rat hepatoma cells were transplanted to the stomach of male Donryu rats. Each hepatic metastatic nodule was collected with the respective primary gastric lesions. Each sample thus obtained was injected separately into the peritoneal cavity of male Donryu rats to make free cancer cells; then, intact cancer cells of the hepatic metastatic and primary gastric lesions were collected. After washing in Dulbecco's phosphate-buffered saline (Ca2+ and Mg(2+)-free, pH 7.2), the definite number of the metastatic and primary gastric cancer cells were incubated in the phosphate-buffered saline containing [1-14C] arachidonic acid at 25 degrees C for 30 min. Arachidonic acid metabolites formed during the incubation period were extracted and subjected to thin-layer chromatography, followed by autoradiography. Each radioactive spot was scraped off the plate and measured for its radioactivity. The pattern of the ability to produce PGs was different between the cancer cells which metastasized to the liver and those of the primary lesions, that is, percentage of PGF2 alpha was higher (p < 0.05) and that of PGE2 was quite higher (p < 0.01) in the hepatic metastatic cancer cells as compared with those of the primary gastric lesion. These results suggest that PGs produced by hepatic metastatic cancer cells might play an important role in hepatic metastatic formation.
 ...
PMID:Some features of prostaglandin synthesis of the cancer cells metastasized into liver from gastric cancer lesions. 827 90

The "Criteria for Evaluating the Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer" are now widely used in Japan. To assess the validity of the criteria, the relation between the antitumor effect evaluated by the criteria and the survival of patients with gastric cancer was analyzed. The subjects were 169 patients with unresectable advanced gastric cancer who were entered into a randomized comparative trial of tegafur plus mitomycin C, or UFT (a combination of uracil and tegafur in a 4:1 molar ratio) plus mitomycin C. Irrespective of their performance status, disease extent and chemotherapy regimen, responding patients showed improved survival over non-responding patients. If the primary gastric lesion responded to chemotherapy, prolongation of survival was noted in patients with a measurable gastric lesion as well as in those with a non-measurable but evaluable gastric lesion. No improvement in survival was recognized among patients having a primary gastric lesion which did not respond to chemotherapy, even if the metastases showed a response. The results obtained in the present study indicate the validity of the criteria, except for diffusely infiltrating gastric lesions.
 ...
PMID:Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. 845 40

A 61-year-old male was admitted after detecting gastric lesion by gastrography in a medical health examination. The patient was diagnosed as Borrmann 2 advanced gastric cancer with remarkable intraperitoneal lymph node metastasis and liver tumor of lateral segment. Relative non-curative gastrectomy was performed with combined partial hepatectomy. The liver tumor measured 1.5 x 1.5 cm and was intraoperatively diagnosed as metastasis of gastric cancer. Mitomycin C 26 mg was given intravenously on the day of operation and 5-fluorouracil (5-FU) 150 mg/day orally since postoperative 14th day as adjuvant chemotherapy. The administration of 5-FU was continued for 5 years. As a result of such combination therapy, the patient still has had no recurrence 8 years following operation.
 ...
PMID:[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival]. 867 42

A 79-year-old man having advanced gastric cancer with liver metastasis was treated by gastric dissection and gastro-jejunostomy. At this time CDDP was injected intraperitoneally at the dose of 30 mg/m2. After operation UFT-E granule was administered orally at the dose of 400 mg/body every day. Two months later he was treated with 5-FU 500 mg/m2 and CDDP 20 mg/m2 intravenously for 3 days. After this treatment, the liver metastatic lesion disappeared and the primary gastric lesion was reduced on CT scan. The same FP chemotherapy was done eight months later. The patient has now survived for more than 1 year and 2 months with a good quality of life by home parenteral nutrition. This UFT-E granule and FP combination therapy seemed to be effective for advanced gastric cancer with liver metastasis.
 ...
PMID:[Successful UFT-E granule and 5-FUCDDP combination therapy for an unresectable advanced gastric cancer complicated with liver metastasis]. 883 44

A 71-year-old man with Borrmann type 3 gastric cancer and peritonitis carcinomatosa was treated with 5'-DFUR 600 mg/body p.o. daily, CDDP 50-80 mg/m2 i.v. on day 1 and MMC 6 mg/m2 i.v. on day 2 after intraperitoneal injection of CDDP and OK-432. The cycle of CDDP and MMC was repeated every 4 or 5 weeks. After 15 cycles of treatment, the primary gastric lesion disappeared and regional lymph node metastasis was reduced. Because of relapsing of the original lesion and concomitant renal dysfunction, a changed regimen of CDDP and Carboplatin was tried. Then the gastric lesion was reduced and lymph node metastasis disappeared. The patient has lived for about 3 years after diagnosis, but his gastric lesion is gradually worsening with duodenal invasion. This case indicates that these combination chemotherapies are quite promising as an effective treatment for advanced gastric cancer and good quality of patient's life.
 ...
PMID:[Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa]. 917 May 28


<< Previous 1 2 3 4 5 6 7 8 9 Next >>